Lamellar’s pipeline is targeted at addressing complex and rare respiratory diseases through two platforms:
LAMELLASOME™ lead therapies, use the unique biophysical properties of LAMELLASOME™ formulations to protect lung tissues in conditions such as Idiopathic Pulmonary Fibrosis (IPF) and Cystic Fibrosis (CF). The lead products are IPF-Lamellasome, a potential first line therapy for the treatment of IPF, and Muco-ease, a disease modifying, mucociliary clearance therapy in CF. The LAMELLASOME™ lead therapies are ready to move into the clinic in a Phase I study covering the nebulised pulmonary LAMELLASOME™ platform.
LAMELLASOME™ gene therapy platform, which use Lamellar’s proprietary Nucleic Acid Transfer (NAT) technology to assist in the intracellular delivery of a broad range of genetic material for the treatment of pulmonary diseases. This potential is demonstrated by two products: LAMELLASOME™ CF-NA for Cystic Fibrosis, and LAMELLASOME™ IPF-NA for Idiopathic Pulmonary Fibrosis.